Auxilium Pharmaceuticals Inc. (Nasdaq: AUXL) blamed lower than expected sales of its Testim testosterone gel for cutting its 2014 revenue and earnings outlook. The stock price plummeted $4.85 to close at $22.51.
Auxilium Cuts Outlook
April 30, 2014 at 10:51 AM EDT
